Deupirfenidone
Breast Cancer Related Lymphoedema
PureTechSmall moleculePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
7 Active assets in the Breast Cancer Related Lymphoedema cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Pycnogenol National Center for Complementary and Integrative Health (NCCIH) | Phase 2 | B |
TACROLIMUS Odense University Hospital | Phase 2/3 | B |
Lymfactin® Herantis Pharma Plc. | Phase 2 | B |
Pentoxifylline M.D. Anderson Cancer Center | Phase 2 | B |
Sodium Selenite University Health Network, Toronto | Phase 2 | B |
View all 17 →
Same molecule, other indications
Deupirfenidone is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →